Skip to main content
Equibles
ZVSA logo

ZVSA · ZyVersa Therapeutics, Inc.

Track ZVSA — free

Use ZVSA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ZVSA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.10 +0.00 (+0.00%) At close · Aug 17
Going-concern doubt — flagged May 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These uncertainties raise substantial doubt about our ability to continue as a going concern for 12 months after the issuance date of our financial statements.”
View the 10-Q filed May 13, 2026
Market Cap
$801,496
Shares
8.10M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.10 Open$0.10 Day$0.10–0.10 52W close$0.10–0.27 Avg vol 30d18K Short int142K · 1.7% float · 7.0d Short vol85% Last earningsNov 14, 2024 DataApr 2024–Aug 2026 Filing10-Q · May 13

Raw chart and full-history price indicators begin at the captured split on Apr 26, 2024; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 15.2 · calm Equity put/call 0.65
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −43%
below
Price vs 50-day avg −29%
below
RSI (14) 41
neutral
MACD trend Positive
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −18%
trailing
6-month return −62%
trailing
YTD return −26%
this year
Relative strength −74%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Distributing
-86% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
1.75% of float · ▬ 0.0% MoM · 7.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1 holders — near 3-yr low, contrarian setup
Squeeze score 54
elevated · 0–100
Fundamentals
Excellent
EPS growth +51%
Y/Y
Balance sheet $928.4K
net cash
Quant / Vol
risk profile
Very High
Volatility 135%
annualized · 1-yr
Max drawdown −63%
past year
ATR 15.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−43% Bearish
Price vs 50-day avg
−29% Bearish
RSI (14)
41 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Distributing
-86% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
1.75% of float · ▬ 0.0% MoM · 7.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $0
vs 200-day avg -43% vs 50-day avg -29%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ZVSA
ZyVersa Therapeutics, Inc.
this stock
$801,496 -26.1% — — 1.7%
ONC
BeOne Medicines Ltd.
 $535.83B +19.3% +22179.2% 823.9 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +13.7% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $84.27B +4.4% +20.8% 20.3 3.3%
ARGX
Argenx SE
 $52.94B +17.5% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
1
% held
0.0%
Net QoQ
-66.1K sh
Top holder
Guerra Advisors Inc
Held Float
View
Short & Settlement
Short Interest
Shares short
141.6K
Days to cover
7.0d
Change
0 sh
View
Short Volume
Short vol %
85%
As of
Jul 31, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$0
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-25.0M
EPS diluted
$-4.18
View
Filings
SEC Filings
Latest
8-K
Filed
Jul 16, 2026
This year
5
View
Earnings & Events
Earnings Calls
Last call
Nov 14, 2024
View

Performance

Raw-price comparisons begin at the captured split on Apr 26, 2024; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
ZVSA -10.5% -17.5% -61.9% -2.0% -26.1%
SPY -0.1% +4.1% +12.4% +3.4% +13.3%
vs SPY -10.4% -21.6% -74.3% -5.4% -39.4%
Key facts CIK 1859007 CUSIP 98987D300 Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)